- Home
- CANG vs ERAS Comparison
CANG vs ERAS Comparison
Compare CANG & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANG
- ERAS
- Stock Information
- Founded
- CANG 2010
- ERAS 2018
- Country
- CANG China
- ERAS United States
- Employees
- CANG N/A
- ERAS N/A
- Industry
- CANG Computer Software: Prepackaged Software
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- CANG Technology
- ERAS Health Care
- Exchange
- CANG Nasdaq
- ERAS Nasdaq
- Market Cap
- CANG 544.1M
- ERAS 484.4M
- IPO Year
- CANG 2018
- ERAS 2021
- Fundamental
- Price
- CANG $4.82
- ERAS $1.42
- Analyst Decision
- CANG Strong Buy
- ERAS Strong Buy
- Analyst Count
- CANG 1
- ERAS 6
- Target Price
- CANG $8.00
- ERAS $4.83
- AVG Volume (30 Days)
- CANG 823.4K
- ERAS 855.6K
- Earning Date
- CANG 08-28-2025
- ERAS 08-11-2025
- Dividend Yield
- CANG N/A
- ERAS N/A
- EPS Growth
- CANG N/A
- ERAS N/A
- EPS
- CANG 0.00
- ERAS N/A
- Revenue
- CANG $247,219,627.00
- ERAS N/A
- Revenue This Year
- CANG $431.64
- ERAS N/A
- Revenue Next Year
- CANG $23.36
- ERAS N/A
- P/E Ratio
- CANG $2,589.59
- ERAS N/A
- Revenue Growth
- CANG 46.60
- ERAS N/A
- 52 Week Low
- CANG $1.40
- ERAS $1.01
- 52 Week High
- CANG $9.66
- ERAS $3.31
- Technical
- Relative Strength Index (RSI)
- CANG 45.45
- ERAS 42.90
- Support Level
- CANG $4.73
- ERAS $1.53
- Resistance Level
- CANG $5.14
- ERAS $1.81
- Average True Range (ATR)
- CANG 0.27
- ERAS 0.12
- MACD
- CANG -0.07
- ERAS -0.01
- Stochastic Oscillator
- CANG 8.33
- ERAS 15.96
About CANG Cango Inc. each representing two (2)
Cango Inc through its subsidiaries, variable interest entities (VIEs), and subsidiaries of the VIEs, are principally engaged in bitcoin mining business, and the automobile trading transaction, automotive financing facilitation, and aftermarket service facilitation businesses (collectively, the automobile and related businesses). The Company conducts the bitcoin mining business mainly through its subsidiaries, and the automobile and related businesses are conducted through the Company's VIEs and the subsidiaries of the VIEs. The company derives majority of its revenue from the bitcoin mining business.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.